# Patients With High-grade Pancreatic Neuroendocrine Tumors

> **NCT07121478** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **National Cancer Center, Korea** · enrollment: 46 (estimated)

## Conditions studied

- Neuroendocrine Tumor of Pancreas
- Pancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Lurbinectedin 4 MG Injection [Zepzelca]

## Key facts

- **NCT ID:** NCT07121478
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-23
- **Primary completion:** 2027-03-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121478, "Patients With High-grade Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07121478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*